Trial
NCT04329806
Sympathetic Mechanisms in the Cardiovascular and Metabolic Alterations of Obesity
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Italo Biaggioni
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Condition
Obesity-Associated Insulin Resistance
Intervention
Moxonidine 0.2 MG
Why stopped
Study being replaced by crossover design
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-05